death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenobarbitalMonitor Closely (1)phenobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.phentermineMonitor Closely (2)prochlorperazine, phentermine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrineMonitor Closely (2)prochlorperazine, phenylephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrine POMonitor Closely (2)prochlorperazine, phenylephrine PO. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .pholcodineMonitor Closely (1)prochlorperazine and pholcodine both increase sedation. Use Caution/Monitor.pimozideContraindicated (1)prochlorperazine and pimozide both increase QTc interval. Contraindicated.Monitor Closely (2)pimozide and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. pimozide and prochlorperazine both increase sedation. Use Caution/Monitor.pirbuterolMonitor Closely (1)prochlorperazine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.porfimerMonitor Closely (1)prochlorperazine, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.posaconazoleMonitor Closely (1)prochlorperazine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.pralidoximeMonitor Closely (3)pralidoxime decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. pralidoxime decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pramipexoleSerious - Use Alternative (1)prochlorperazine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.primaquineMonitor Closely (1)primaquine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.primidoneMonitor Closely (1)primidone and prochlorperazine both increase sedation. Use Caution/Monitor.procainamideContraindicated (1)prochlorperazine and procainamide both increase QTc interval. Contraindicated.procarbazineMonitor Closely (1)procarbazine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Excessive sedation.promazineSerious - Use Alternative (1)prochlorperazine and promazine both increase QTc interval. Avoid or Use Alternate Drug.promethazineMonitor Closely (2)prochlorperazine and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. promethazine and prochlorperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and promethazine both increase QTc interval. Avoid or Use Alternate Drug.propafenoneMonitor Closely (1)propafenone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propanthelineMonitor Closely (3)propantheline decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. propantheline decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.propofolMonitor Closely (1)propofol and prochlorperazine both increase sedation. Use Caution/Monitor.propylhexedrineMonitor Closely (2)prochlorperazine, propylhexedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylineMonitor Closely (2)prochlorperazine and protriptyline both increase QTc interval. Use Caution/Monitor. prochlorperazine and protriptyline both increase sedation. Use Caution/Monitor.Minor (2)protriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. protriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.pseudoephedrineMonitor Closely (1)prochlorperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.pyrimethamineMinor (1)pyrimethamine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.quazepamMonitor Closely (1)quazepam and prochlorperazine both increase sedation. Use Caution/Monitor.quetiapineMonitor Closely (2)prochlorperazine and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. prochlorperazine and quetiapine both increase sedation. Use Caution/Monitor.quinacrineMinor (1)quinacrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.quinaprilMinor (1)prochlorperazine increases effects of quinapril by unspecified interaction mechanism. Minor/Significance Unknown.quinidineContraindicated (1)prochlorperazine and quinidine both increase QTc interval. Contraindicated.Monitor Closely (1)quinidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)quinidine, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive cardiac effects.ramelteonMonitor Closely (1)prochlorperazine and ramelteon both increase sedation. Use Caution/Monitor.ramiprilMinor (1)prochlorperazine increases effects of ramipril by unspecified interaction mechanism. Minor/Significance Unknown.ranolazineMonitor Closely (1)prochlorperazine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.Minor (1)ranolazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.rapacuroniumMonitor Closely (3)rapacuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. rapacuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rimabotulinumtoxinBMonitor Closely (1)prochlorperazine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.risperidoneMonitor Closely (3)prochlorperazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely. prochlorperazine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. prochlorperazine and risperidone both increase sedation. Use Caution/Monitor.ritonavirMinor (1)ritonavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.rocuroniumMonitor Closely (3)rocuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. rocuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.ropiniroleSerious - Use Alternative (1)prochlorperazine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamideSerious - Use Alternative (1)prochlorperazine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.sageMinor (1)prochlorperazine and sage both increase sedation. Minor/Significance Unknown.salmeterolMonitor Closely (1)prochlorperazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.saquinavirSerious - Use Alternative (1)saquinavir, prochlorperazine. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Increased risk of QT prolongation and cardiac arrhythmias.scopolamineMonitor Closely (3)scopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. scopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.scullcapMonitor Closely (1)prochlorperazine and scullcap both increase sedation. Use Caution/Monitor.secobarbitalMonitor Closely (1)secobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.selinexorSerious - Use Alternative (1)selinexor, prochlorperazine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.serdexmethylphenidate/dexmethylphenidateMonitor Closely (1)prochlorperazine, serdexmethylphenidate/dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.sertralineMonitor Closely (1)sertraline and prochlorperazine both decrease QTc interval. Use Caution/Monitor.Minor (1)sertraline will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.sevofluraneMonitor Closely (2)sevoflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor. sevoflurane and prochlorperazine both increase sedation. Use Caution/Monitor.shepherd's purseMonitor Closely (1)prochlorperazine and shepherd's purse both increase sedation. Use Caution/Monitor.siponimodMonitor Closely (1)siponimod and prochlorperazine both decrease QTc interval. Use Caution/Monitor.smokingMonitor Closely (1)smoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.sodium oxybateSerious - Use Alternative (1)prochlorperazine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.solifenacinMonitor Closely (4)solifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. solifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. solifenacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.sotalolContraindicated (1)prochlorperazine and sotalol both increase QTc interval. Contraindicated.stiripentolMonitor Closely (1)stiripentol, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.sufentanilMonitor Closely (1)sufentanil and prochlorperazine both increase sedation. Use Caution/Monitor.sulfamethoxazoleMonitor Closely (1)prochlorperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sunitinibMonitor Closely (1)sunitinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.tacrolimusMonitor Closely (1)tacrolimus and prochlorperazine both decrease QTc interval. Use Caution/Monitor.tapentadolMonitor Closely (1)tapentadol and prochlorperazine both increase sedation. Use Caution/Monitor.teduglutideMonitor Closely (1)teduglutide increases levels of prochlorperazine by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.telavancinMonitor Closely (1)prochlorperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamMonitor Closely (1)temazepam and prochlorperazine both increase sedation. Use Caution/Monitor.terbutalineMonitor Closely (1)prochlorperazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazineMonitor Closely (1)prochlorperazine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)tetrabenazine and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.thioridazineMonitor Closely (2)prochlorperazine and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. prochlorperazine and thioridazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)thioridazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.thiothixeneMonitor Closely (2)prochlorperazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. prochlorperazine and thiothixene both increase sedation. Use Caution/Monitor.tiotropiumMonitor Closely (3)tiotropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. tiotropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tipranavirMinor (1)tipranavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.tobacco useMonitor Closely (1)tobacco use decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.tolterodineMonitor Closely (3)tolterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. tolterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.topiramateMonitor Closely (1)prochlorperazine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadolMonitor Closely (1)tramadol and prochlorperazine both increase sedation. Use Caution/Monitor.trandolaprilMinor (1)prochlorperazine increases effects of trandolapril by unspecified interaction mechanism. Minor/Significance Unknown.trazodoneMonitor Closely (2)prochlorperazine and trazodone both increase QTc interval. Use Caution/Monitor. prochlorperazine and trazodone both increase sedation. Use Caution/Monitor.Minor (2)trazodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects. trazodone, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.tretinoinSerious - Use Alternative (1)prochlorperazine, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.tretinoin topicalSerious - Use Alternative (1)prochlorperazine, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.triazolamMonitor Closely (1)triazolam and prochlorperazine both increase sedation. Use Caution/Monitor.triclofosMonitor Closely (1)triclofos and prochlorperazine both increase sedation. Use Caution/Monitor.trifluoperazineMonitor Closely (2)prochlorperazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. prochlorperazine and trifluoperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.trihexyphenidylMonitor Closely (2)trihexyphenidyl decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimMonitor Closely (1)prochlorperazine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipramineMonitor Closely (2)prochlorperazine and trimipramine both increase QTc interval. Use Caution/Monitor. prochlorperazine and trimipramine both increase sedation. Use Caution/Monitor.Minor (2)trimipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. trimipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.triprolidineMonitor Closely (1)triprolidine and prochlorperazine both increase sedation. Use